Screening of Potential Hub Genes in Glioma Progression Based on Bioinformatics Analysis
Objectives: Glioma is the most common primary tumor of the central nervous system, and its therapeutic effect is not optimistic. In recent years, related therapeutic technologies have developed rapidly, but unfortunately, the improvement of clinical therapeutic effect is not satisfactory. In addition to conventional therapies, there are some attractive therapies, such as biological therapy (immunotherapy), gene therapy, etc. Therefore, searching for potential target genes of glioma is of great significance for developing new therapeutic directions and designing new biomarkers. Methods: Download gene expression data set, GSE137902 gelatin and GSE13790 matrix through NCBI-G to screen overlapping differential expression genes (DEGs). In order to identify central genes from these genes, we conducted protein protein interaction (PPI) network. To further explore the potential mechanism of central genes in glioma, we performed gene ontology (GO) and Kyoto Gene and Genome Encyclopedia (KEGG) analysis. Then get the intersection of key genes according to five algorithms of Closeness Degree EPC MCC Stress. The intersection is obtained through GSE117423, GSE188256 and GSE90598 in geo database, and finally verified through Receiver Operating Characteristic (ROC) curve. Results: A total of 1274 differentially expressed genes are identified, and then 309 genes are obtained by intersection of the two. 16 Hub genes were obtained, and then the intersection of the two genes with GSE117423, GES188256 and GSE90598 genes was verified to obtain the key gene TIMP1 of glioma. Made the ROC curve of key gene.The intersection with hub gene was determined to identify TIMP1 as the key gene. Conclusion: The DEGs and Hub genes and signal pathways found in this study can confirm that the key gene TIMP1 is closely related to the occurrence and evolution of glioma, and provide candidate targets for the diagnosis and treatment of glioma.
Rowlands IJ, et al. "Prevalence and incidence of endometriosis in Australian women: a data linkage cohort study." BJOG: An International Journal of Obstetrics & Gynaecology 128.4 (2021): 657-665.
Cea Soriano, Lucia, et al. "Incidence, treatment and recurrence of endometriosis in a UK-based population analysis using data from The Health Improvement Network and the Hospital Episode Statistics database." The European Journal of Contraception & Reproductive Health Care 22.5 (2017): 334-343.
Grundström, Hanna, et al. "Healthcare consumption and cost estimates concerning Swedish women with endometriosis." Gynecologic and obstetric investigation 85.3 (2020): 237-244.
Simoens, Steven, et al. "The burden of endometriosis: costs and quality of life of women with endometriosis and treated in referral centres." Human Reproduction 27.5 (2012): 1292-1299.
Eisenberg, Vered H., et al. "Burden of endometriosis: infertility, comorbidities, and healthcare resource utilization." Journal of Clinical Medicine 11.4 (2022): 1133.
Soliman, Ahmed M., et al. "Real-world evaluation of direct and indirect economic burden among endometriosis patients in the United States." Advances in therapy 35 (2018): 408-423.
Fuldeore, Mahesh, et al. "Healthcare utilization and costs in women diagnosed with endometriosis before and after diagnosis: a longitudinal analysis of claims databases." Fertility and sterility 103.1 (2015): 163-171.
Soliman, Ahmed M., et al. "Health care utilization and costs associated with endometriosis among women with medicaid insurance." Journal of managed care & specialty pharmacy25.5 (2019): 566-572.
Surrey, Eric, et al. "Impact of endometriosis diagnostic delays on healthcare resource utilization and costs." Advances in Therapy 37 (2020): 1087-1099.
Copyright (c) 2023 Chengzhi Cui, Shi Yin, Lei Meng, Jiaming Huang, Dong Chen
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors submitting to USP journals agree to publish their manuscript under the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0) where authors agree to allow third parties to share their work (copy, distribute, transmit) and to adapt it, under the condition that the authors are given credit, and that in the event of reuse or distribution, the terms of this license are made clear
Authors retain copyright of their work, with first publication rights (online and print) granted to Universe Scientific Publishing or the owner of the journal in question.